A targeted drug delivery system based on DNA tetrahedral nanoclusters and its construction method and application
By designing a targeted drug-loading system based on DNA tetrahedral nanoclusters, the problems of low drug-loading efficiency and insufficient targeting capabilities of existing DNA nanostructured carriers are solved, and efficient and accurate tumor targeting and drug delivery are achieved.
Patent Information
- Application Number
- CN202210798779.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-07-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-07-06
AI Technical Summary
Due to the low drug loading efficiency and sensitivity to endogenous nucleases, existing DNA nanostructured carriers lead to drug leakage and loss of tumor targeting ability in vivo, lack of cell type-specific recognition ability and high loading rate.
A targeted drug-loading system based on DNA tetrahedral nanoclusters was designed to achieve specific and efficient targeting through the composition of small DNA building blocks stacked with multi-layered layers and chemotherapeutic drugs with multivalent nucleic acid aptamers and physical insertion layers. Tumor.
实现了高载药量、精准控制治疗药物配比、在正常生理环境中长期稳定,并可选择性在肿瘤微环境中释放药物,显著提高了抗癌药物的靶向效率和疗效。
Smart Images

Figure CN116077670B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology and biomedicine technology, and specifically relates to a targeted drug delivery system based on DNA tetrahedral nanoclusters and a construction method and application thereof. Background Art
[0002] As we all know, chemotherapeutic drugs are widely used in cancer treatment. Although chemotherapy is one of the most widely used clinical methods for cancer treatment, the off-target toxicity of chemotherapeutic agents to healthy tissues and organs hinders its further clinical application. Ideal biocompatibility, high loading capacity and sufficient accumulation at the tumor site are three prerequisites for promising chemotherapeutic drug delivery carriers to ensure high concentrations of drugs in tumor tissues and reduce off-target effects. Although nanostructures made entirely of DNA with natural biocompatibility, high programmability and negligible immunogenicity show great potential as anticancer drug delivery carriers, current DNA nanostructure carriers may lead to early drug leakage in vivo and / or loss of tumor targeting ability due to their relatively low drug loading efficiency and inherent sensitivity to endogenous nucleases. Therefore, it is imperative to develop ideal therapies with cell type-specific recognition capabilities, high drug loading rates and responsive release of drugs in the tumor microenvironment.
[0003] As a naturally occurring biomacromolecule, DNA is highly water-soluble and biocompatible. Due to its unique Watson-Crick base pairing characteristics, ease of synthesis, and well-defined structure, DNA is an ideal element for self-assembly and can be controllably assembled into one-, two-, and three-dimensional (1D, 2D, and 3D) nanostructures. Due to the polymeric nature of DNA assemblies, the flexibility and rigidity of DNA assemblies can be easily adjusted by changing the number of sticky end base pairs and regulating the binding of ssDNA and dsDNA. Considerable research progress has also been made in the use of these DNA nanostructures as drug delivery carriers in diagnosis and therapy through their inherent recognition ability, nonspecific uptake, or functionalization with targeting groups. In addition, preliminary studies have shown that dense DNA nanostructures (such as DNA tetrahedrons) have stronger resistance to nuclease degradation and better cellular uptake properties. However, nucleic acid nanocarriers still have some shortcomings in terms of effective drug delivery, such as lack of tumor targeting activity. So far, researchers have developed a variety of ligands for targeted drug delivery, including antibodies, peptides, small molecules, and aptamers. Compared with widely used antibodies, aptamers have the advantages of low production cost, low immunogenicity and toxicity, fast tissue penetration, and high binding affinity, making them ideal for targeted delivery of conventional chemotherapeutic drugs. Aptamers are short single-stranded oligonucleotides with unique intramolecular conformations and specific recognition capabilities for homologous targets. More interestingly, aptamers can be easily integrated into DNA nanostructures without any chemical modification. In this regard, a number of aptamer-integrated DNA nanostructures have been proposed for targeted drug delivery to improve efficacy and reduce side effects.
[0004] Currently, drug delivery based on DNA nanostructures is mainly targeted at cancer cells. As a promising candidate for drug delivery, DNA nanostructures can easily pass through membrane barriers and have a series of excellent characteristics, including: (1) predictable and well-defined structure; (2) high drug loading capacity; (3) excellent biocompatibility; (4) structural stability under physiological conditions; (5) ability to be internalized by cells. With these advantages, DNA nanostructures have been used to construct chemotherapeutic drug loading platforms in vivo and in vitro. The unique feature of nucleic acid nanostructured drug delivery systems is modularity, which means that the size of nucleic acid nanoobjects and the location of modifications (ligands or drug molecules) on or in them can be precisely controlled at the nanoscale, and the shape and flexibility of nucleic acid objects can also be fine-tuned. It is this modularity that makes nucleic acid nanotechnology a powerful platform that can introduce many aspects in a controllable manner for the precise delivery of targeted anticancer drugs.
[0005] Based on the above reasons, we designed a targeted drug delivery system based on DNA tetrahedral nanoclusters, which consists of multi-layer stacked small DNA building blocks (DNA tetrahedral units) with multivalent nucleic acid aptamers and physically inserted layers of chemotherapeutic drugs to specifically and efficiently target tumors. The assembly process of the targeted drug delivery system is controllable, and the size of the DNA tetrahedral nanoclusters is uniform and stable. The targeted drug delivery system can selectively target target cells due to the loading of nucleic acid aptamers, and different targeting aptamers can be designed for different target cells. The targeted drug delivery system has a high drug loading capacity, can accurately control the ratio of therapeutic drugs, and is long-term stable in normal physiological environments, and can be selectively released in the tumor microenvironment. The targeted drug delivery system can selectively deliver anticancer drugs to target cells and kill cancer cells due to the loading of anticancer drugs, showing great potential in anticancer treatment. In addition, the nucleic acid aptamers on the surface of the DNA tetrahedral nanoclusters will be non-specifically degraded during transportation, while the internal nucleic acid aptamers can move to the surface to compensate for the degradation of the surface nucleic acid aptamers, further maintaining the specificity of the nanoclusters. This assembly method can ensure that the drug delivery system has excellent targeting effects during the delivery process. In summary, the targeted drug delivery system based on DNA tetrahedral nanoclusters constructed by the present invention has the advantages of simple design and preparation, good biocompatibility, high loading capacity, and selective recognition, which makes the targeted drug delivery system based on DNA tetrahedral nanoclusters an effective platform for multifunctional bioimaging and drug delivery. Summary of the invention
[0006] The purpose of the present invention is to prepare a precise targeted drug delivery system of DNA nanoclusters based on DNA tetrahedron basic units, and further provide a targeted drug delivery system based on DNA tetrahedron nanoclusters and a preparation method and application thereof.
[0007] To achieve the above object, the present invention adopts the following technical solution:
[0008] The present invention first provides a targeted drug delivery system based on DNA tetrahedron nanoclusters, wherein the drug delivery system is composed of a DNA tetrahedron assembled from seven DNA probes (six of which are modified with phosphorylation groups at the 5' end of the DNA sequence), T4 DNA ligase, sgc8 nucleic acid aptamer probes and anticancer drugs;
[0009] The anticancer drug is an anthracycline or other anticancer drug;
[0010] The seven DNA probes used to assemble the DNA tetrahedron are as follows:
[0011] DNA tetrahedral assembly probe 1 (T1): 5'-p-AGGAGATACACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCGATCAGGCAGGGTCCAAT-3',
[0012] DNA Tetrahedron Assembly Probe 2 (T2): 5'-p-GCAGTTGACACGAACATTCCTAAGTCTGAAATTTATCCATCGCCATAGTAGACCTATCACCGTGGAAG -3',
[0013] DNA Tetrahedron Assembly Probe 3 (T3): 5'-ATGGACCATCTCGAGACATATTTCGTGTAGCAAGCTGTAATCGACTCTACCCTAAGTAAGCAAGACACAACTACTATGGCGATGGATAAA-3',
[0014] DNA Tetrahedral Assembly Probe 4 (T4): 5'-p-TAAGCCAGCCATAAGTCAGTATCTCCTATTGGACCCTGCCTGAACACTGATCCG-3',
[0015] DNA tetrahedral assembly probe 5 (T5): 5'-p-GCGAGTATGGAGTCAACTGCCTTCCACGGTGATAGGATCGAATGCTGGATACGT-3',
[0016] DNA tetrahedral assembly probe 6 (T6): 5'-p-CAGCATTCGAAGTCCAGTTTCTGGACATGTGTCTTGCTTACTTAGGGTAGAGAACCACGTTTCGTGGTAGACTTATGGC-3',
[0017] DNA tetrahedral ligation probe (LS): 5′-p-TGGCTTACGGATCAGTGAACCATACTCGCACGTATC-3′;
[0018] The sgc8 nucleic acid aptamer probe is: 5'-TATGTCTCGAGATGGTCCATTTTTTATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA-3'.
[0019] The present invention further provides a method for constructing the above-mentioned targeted drug delivery system based on DNA tetrahedral nanoclusters, comprising the following steps:
[0020] S1: Construction of targeted DNA nanocluster materials based on DNA tetrahedron:
[0021] S1-1: First, take 0.5 µL of each of the DNA probes T1~T6 and LS, each with a concentration of 10 µM, add them together with 2.5 µL of 10×T4 DNA ligase buffer (400 mM Tris-HCl, 100 mM MgCl2, 100 mM dithiothreitol, 5 mM adenosine triphosphate, pH=7.8) and 18 µL of ultrapure water into a 0.5 mL centrifuge tube, and mix thoroughly using a micropipette;
[0022] S1-2: Place the mixed solution obtained in step S1-1 on a metal heating block, heat at 90°C for 5 minutes, and then gradually cool to room temperature to ensure successful assembly of DNA tetrahedrons (this cooling process takes about 1-2 hours);
[0023] S1-3: After step S1-2 is completed, 0.5 µL of 10 µM sgc8 aptamer is added to the reaction solution and incubated at 37°C for 2 h to obtain a DNA tetrahedral structure configured by sgc8;
[0024] S1-4: After step S1-3, add 0.5 µL of 400 U / µL T4 DNA ligase to the reaction solution and incubate overnight at 16°C to promote the assembly of targeted DNA nanoclusters;
[0025] S1-5: After step S1-4 is completed, the reaction solution is inactivated at 65° C. for 10 minutes to stop the reaction, thereby obtaining the DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC);
[0026] S2: Construction of targeted drug delivery system based on DNA tetrahedral nanoclusters:
[0027] The targeted DNA nanocluster material sgc8-eNC (final concentration of 3.5 nM) prepared in step S1 and the anticancer drug (final concentration of 20 µM) were co-incubated in 1×T4 DNA ligase buffer and incubated overnight in a dark environment at 37°C. After the incubation was completed, the targeted drug delivery system based on DNA tetrahedral nanoclusters was obtained.
[0028] The present invention also provides a universal targeted drug delivery system transformed from the above-mentioned targeted drug delivery system, wherein the universal targeted drug delivery system is obtained by changing the sequence of the nucleic acid aptamer probe in the drug delivery system according to the target cells.
[0029] Furthermore, the universal targeted drug delivery system is obtained by changing the sequence of the nucleic acid aptamer probe in the drug delivery system for the target cell MCF-7 human breast cancer cell; the sequence of the changed nucleic acid aptamer probe is:
[0030] 5'-TATGTCTCGAGATGGTCCATTTTTTGGTGGTGGTGGTTGTGGTGGTGGTGG-3'.
[0031] Furthermore, the universal targeted drug delivery system is obtained by changing the sequence of the nucleic acid aptamer probe in the drug delivery system for the target cell A549 adenocarcinoma human alveolar basal epithelial cells; the sequence of the changed nucleic acid aptamer probe is:
[0032] 5'-TATGTCTCGAGATGGTCCATTTTTTTGTGGCCAGTCACTCAATTGGGTGTAGGGGTGGGGATTGTGGGTTG-3'.
[0033] The present invention also provides the use of the above-mentioned targeted drug delivery system based on DNA tetrahedron nanoclusters in the preparation of targeted tumor drugs, wherein the tumor is selected from leukemia, lymphoma, breast cancer, uterine cancer, ovarian cancer and lung cancer.
[0034] The present invention also provides application of the above-mentioned targeted drug delivery system based on DNA tetrahedron nanoclusters in biological imaging.
[0035] In the above-mentioned targeted drug delivery system based on DNA tetrahedron nanoclusters, part of the DNA probes constituting the DNA tetrahedron are modified with phosphorylated groups, and the modified structure can ensure that the DNA chain forms a firm DNA tetrahedron structure and a DNA nanocluster structure under the action of T4 DNA ligase. In the above-mentioned method for constructing a targeted drug delivery system based on DNA tetrahedron nanoclusters, sgc8 nucleic acid aptamers are first used to successfully assemble with DNA tetrahedrons, and then DNA ligase is used to assemble the DNA tetrahedrons with targeting effects into DNA nanoclusters. The sgc8 nucleic acid aptamers on the surface of the DNA nanoclusters will be non-specifically degraded during transportation, while the internal sgc8 aptamers can move to the surface to compensate for the degradation of the surface sgc8 nucleic acid aptamers, further maintaining the specificity of the nanoclusters. This assembly method can ensure that the drug delivery system has excellent targeting effects during the delivery process.
[0036] The inventive principle of the present invention is as follows:
[0037] First, through the pre-designed base sequence complementarity principle, seven single-stranded DNA probes are self-assembled into DNA building blocks, namely tetrahedral basic units, through a simple annealing process. There are two design requirements for DNA probes: first, some DNA probes have a phosphorylation group at the 5' end, which can make the DNA structure more stable under the action of T4 DNA ligase, and can be assembled into a DNA nanocluster structure from the DNA tetrahedral basic units; second, the unique design of the ligation probe can make the DNA tetrahedral basic unit stable at room temperature, and can form a DNA nanocluster structure with stable size under the action of T4 DNA ligase. See the schematic diagram of the design of the DNA tetrahedral basic unit. Figure 1 .
[0038] Since nucleic acid aptamers can give DNA nanomaterials targeted selectivity, the present invention combines nucleic acid aptamers with DNA nanoclusters to form a targeted DNA nanocluster material based on DNA tetrahedron. The structure of the DNA tetrahedron basic unit we designed allows the sticky ends to point in four different directions. When the temperature is relatively low, the sticky end hybridization between tetrahedral units is relatively stable. Under this low temperature condition, ligase (T4 DNA ligase) is added to connect most of the gaps, thus forming a stable sgc8 nucleic acid aptamer probe-loaded DNA nanocluster (sgc8-eNC). See the construction flow chart of the targeted DNA nanocluster material based on DNA tetrahedron. Figure 2 .
[0039] Since the self-assembled DNA tetrahedrons have a rigid structure, the constructed DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC) has excellent stability. At the same time, the small tetrahedral units arranged layer by layer provide a large number of spatially addressable sites, allowing them to be combined with small molecule fluorophores or therapeutic agents. Doxorubicin (Dox), as a typical chemotherapy anticancer drug, is loaded onto sgc8-eNC to form the final DNA tetrahedron-based targeted DNA nanocluster drug delivery system (Dox-sgc8-eNC). When Dox-sgc8-eNC is incubated with different types of cells, it specifically targets the target cells and selectively delivers anticancer drugs into the target cells, thereby killing cancer cells. The schematic diagram of the targeted drug delivery system based on DNA tetrahedral nanoclusters for cell targeting and treatment is shown in Figure 2 .
[0040] The advantages of the present invention are:
[0041] The targeted drug delivery system based on DNA tetrahedral nanoclusters constructed by the present invention has the following advantages:
[0042] (1) The assembly process of the targeted drug delivery system is controllable, and the size of the DNA tetrahedral nanoclusters is uniform and stable. The unique DNA design allows the DNA chains to assemble into a three-dimensional skeleton structure, and the phosphorylation group modification at the end can ensure that the DNA chains can form a strong DNA tetrahedral structure and DNA nanocluster structure under the action of T4 DNA ligase.
[0043] (2) The targeted drug delivery system has good stability. First, compared with ordinary DNA nanomaterials, DNA tetrahedral nanoclusters have significantly enhanced serum stability; second, the nucleic acid aptamers on the surface of DNA tetrahedral nanoclusters will be non-specifically degraded during transportation, while the nucleic acid aptamers inside can move to the surface to compensate for the degradation of the surface nucleic acid aptamers, further maintaining the specificity of the nanoclusters. This assembly method can ensure that the drug delivery system has excellent targeting effect during the delivery process.
[0044] (3) Since the targeted drug delivery system is loaded with nucleic acid aptamers, it can selectively target target cells, and different targeting aptamers can be designed for different target cells, which can be used to prepare a universal targeted drug delivery system.
[0045] (4) This targeted drug delivery system has an ultra-high drug loading capacity and can precisely control the ratio of therapeutic drugs. It is also stable for a long time in a normal physiological environment and can be selectively released in the tumor microenvironment.
[0046] (5) This targeted drug delivery system can selectively deliver anticancer drugs to target cells and kill cancer cells, showing great potential in anticancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 : Schematic diagram of the design of the basic unit of DNA tetrahedron in targeted DNA nanoclusters. The DNA tetrahedron contains five sticky ends, four of which are designed on the terminal triangular base (sticky end-ia, sticky end-ib, sticky end-ii, sticky end-iii), and the adjacent triangular bases are not on the same plane (sticky end-ia and sticky end-ib are located on vertex i, sticky end-ii is located on vertex ii, and sticky end-iii is located on vertex iii), forming a three-dimensional skeleton assembly; another vertex is used for the connection of nucleic acid aptamers (sticky end-iv, which is located on vertex iv). Some DNA modified phosphorylation groups (T1, T2, T4, T5, T6 and LS) can ensure the efficient connection of the material under the action of T4 DNA ligase, while the unphosphorylated sticky end iv can ensure the normal connection of the aptamer, and is conducive to the sgc8 aptamer to move to the surface to compensate for the degradation of surface sgc8, further maintaining the specificity of the nanocluster.
[0048] Figure 2 : Schematic diagram of the construction process of targeted DNA nanocluster materials based on DNA tetrahedron and their application in cell targeting and therapy.
[0049] Figure 3 : Characterization diagram of targeted DNA nanocluster materials based on DNA tetrahedron. Wherein A is the polyacrylamide gel electrophoresis analysis of targeted DNA nanocluster materials: Lane M represents the DNA standard band; Lane 1 is the hybridization product of three probes (T1, T2 and T3), which constitute the basic skeleton of DNA tetrahedron; Lane 3 is the hybridization product of T1, T2, T3 and T4; Lane 4 is the hybridization product of six probes, namely T1, T2, T3, T4, T5 and T6; Lane 5 is a mixture of T1, T2, T3, T4, T5, T6 and ligation probe, but in the absence of T4 DNA ligase; Lane 6 is a mixture of T1, T2, T3, T4, T5, T6 and ligation probe and sgc8 aptamer probe, but in the absence of T4 DNA ligase; Lane 7 is a mixture of T1, T2, T3, T4, T5, T6 and ligation probe and sgc8 aptamer probe, in the presence of T4 DNA ligase, that is, the final sgc8-eNC material constructed; Figure B is the AFM characterization image of the targeted DNA nanocluster material, which are two-dimensional and three-dimensional structures respectively, and the lower part is the size analysis data of the particle cross-section.
[0050] Figure 4 :Stability analysis of DNA tetrahedron-based targeted DNA nanocluster materials. Figure A shows the polyacrylamide gel electrophoresis analysis data of the targeted DNA nanocluster materials incubated with 10% fresh mouse serum at different time points. Figure B shows the flow cytometry analysis data of the target cells after incubation of the targeted DNA nanocluster materials with 10% fresh mouse serum at different time points.
[0051] Figure 5 :Application of DNA tetrahedron-based targeted DNA nanocluster materials in cell targeting recognition. Laser confocal imaging was used to study the targeting recognition ability of DNA tetrahedron-based targeted DNA nanocluster materials on four types of cells: CEM (A), HeLa (B), Ramos (C) and L02 (D). A and B are target cancer cells recognized by sgc8 aptamers, C is a target cancer cell that is not recognized by sgc8 aptamers, and D is a normal human cell.
[0052] Figure 6 :An investigation of the drug loading capacity and drug selective release of a targeted drug delivery system based on DNA tetrahedron nanoclusters. A is a study on the drug loading capacity of the precise targeted DNA nanocluster drug delivery system. B is the stability of the precise targeted DNA nanocluster drug delivery system.
[0053] Figure 7 :Application of a targeted drug delivery system based on DNA tetrahedral nanoclusters in bio-imaging and tumor targeted drug delivery. A is the application of the targeted drug delivery system in bio-imaging, and B is the tumor volume growth of tumor-bearing mice (HeLa) after targeted drug delivery treatment with the targeted drug delivery system.
[0054] Figure 8 :A universal evaluation of a targeted drug delivery system based on DNA tetrahedral nanoclusters. A is a drug delivery system (AS1411-eNC) targeting MCF-7 cancer cells, which was evaluated using laser confocal imaging; B is a drug delivery system (S6-eNC) targeting A549 cancer cells, which was evaluated using laser confocal imaging. DETAILED DESCRIPTION
[0055] In order to make the contents described in the present invention easier to understand, the technical scheme described in the present invention is further explained below in combination with specific implementation methods. However, the following examples are merely examples of the present invention and do not represent the scope of protection of the rights limited by the present invention. The scope of protection of the present invention shall be subject to the claims.
[0056] Example 1 A method for preparing a targeted drug delivery system based on DNA tetrahedral nanoclusters comprises the following steps:
[0057] S1: Construction of targeted DNA nanoclusters based on DNA tetrahedrons:
[0058] S1-1: Take 0.5 µL of DNA probes T1~T6 and LS, each with a concentration of 10 µM, add them together with 2.5 µL 10×T4 DNA ligase buffer (400 mM Tris-HCl, 100 mM MgCl2, 100 mM dithiothreitol, 5 mM adenosine triphosphate, pH=7.8) and 18 µL ultrapure water into a 0.5 mL centrifuge tube and mix thoroughly using a micropipette;
[0059] S1-2: Place the mixed solution obtained in step S1-1 on a metal heating block, heat at 90°C for 5 minutes, and then gradually cool to room temperature to ensure successful assembly of DNA tetrahedrons (this cooling process takes about 1-2 hours);
[0060] S1-3: After step S1-2 is completed, 0.5 µL of 10 µM sgc8 nucleic acid aptamer probe is added to the reaction solution and incubated at 37 °C for 2 h to form a sgc8-configured DNA tetrahedral structure (abbreviated as sgc8-Tetra);
[0061] S1-4: After step S1-3, add 0.5 µL of 400 U / µL T4 DNA ligase to the reaction solution, mix well and incubate at 16°C overnight to promote the assembly of targeted DNA nanoclusters (sgc8-eNC);
[0062] S1-5: After step S1-3 is completed, the reaction solution is inactivated at 65° C. for 10 minutes to stop the ligase from continuing to react, thereby obtaining the DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC).
[0063] S2: Construction of targeted drug delivery system based on DNA tetrahedral nanoclusters:
[0064] The targeted DNA nanocluster material sgc8-eNC (final concentration of 3.5 nM) prepared in step S1 and doxorubicin (final concentration of 20 µM) were co-incubated in 1×T4 DNA ligase buffer at 37°C overnight in a dark environment. After the incubation, a targeted drug delivery system based on DNA tetrahedral nanoclusters (abbreviated as Dox-sgc8-NC) was obtained.
[0065] Wherein, the DNA probe T1 is:
[0066] 5'-p-AGGAGATACACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCGATCAGGCAGGGTCCAAT-3';
[0067] The DNA probe T2 is: 5'-p-GCAGTTGACACGAACATTCCTAAGTCTGAAATTTATCCATCGCCATAGTAGACCTATCACCGTGGAAG -3';
[0068] The DNA probe T3 is: 5'-ATGGACCATCTCGAGACATATTTCGTGTAGCAAGCTGTAATCGACTCTACCCTAAGTAAGCAAGACACAACTACTATGGCGATGGATAAA-3';
[0069] The DNA probe T4 is:
[0070] 5'-p-TAAGCCAGCCATAAGTCAGTATCTCCTATTGGACCCTGCCTGAACACTGATCCG-3';
[0071] The DNA probe T5 is: 5'-p-GCGAGTATGGAGTCAACTGCCTTCCACGGTGATAGGATCGAATGCTGGATACGT-3';
[0072] The DNA probe T6 is: 5'-p-CAGCATTCGAAGTCCAGTTTCTGGACATGTGTCTTGCTTACTTAGGGTAGAGAACCACGTTTCGTGGTAGACTTATGGC-3';
[0073] The DNA probe LS is: 5'-p-TGGCTTACGGATCAGTGAACCATACTCGCACGTATC-3';
[0074] The sgc8 nucleic acid aptamer probe (sgc8) is: 5'-TATGTCTCGAGATGGTCCATTTTTTATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA-3'.
[0075] Figure 3 A is the polyacrylamide gel electrophoresis analysis of sgc8-eNC. Figure 3 As shown in A, the DNA probes are located at different positions due to their inherent electrophoretic mobility, and the bands of each DNA component or assembly intermediate can be clearly observed. Lane 1 is the hybridization product of T1, T2 and T3 probes (i.e., the basic skeleton of the DNA tetrahedron). Subsequently, DNA sequences are added one by one to this skeleton, as shown in lanes 2 to 6, which will cause obvious mobility changes, revealing the formation of different DNA assemblies. Lane 6 is a mixture of T1, T2, T3, T4, T5, T6 and LS probes and sgc8 aptamer probes (i.e., the basic structural unit of the aptamer-bound tetrahedron), and lane 7 is sgc8-eNC. It can be seen that with the addition of T4 ligase, a non-penetrating band blocking the hole appears, indicating that a DNA nanocluster structure with extremely high molecular weight and spatial complexity has been successfully formed. At the same time, the structure of the prepared targeted DNA nanocluster material sgc8-eNC was characterized by AFM, as shown in Figure 3 As shown in B, the results show that its morphology is similar to a sphere, and the height of this spherical structure is about 36 (± 2) nm and the width is about 200 (± 30) nm, which is obviously a three-dimensional DNA nanostructure.
[0076] Example 2 Serum stability analysis of DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC)
[0077] First, a DNA tetrahedron-based targeted DNA nanocluster material was constructed according to the method of Example 1 (the difference is that the original sgc8 aptamer probe was replaced by a sgc8 aptamer probe labeled with a FAM fluorescent group), and then the samples were mixed with fresh mouse serum to make the final serum content 10 vol%, and then incubated at 37 ° C for 0, 0.5, 1, 2, 4, 6 and 8 hours. After the experiment, the mixed sample was mixed with 6 × Loading buffer, and then the product was analyzed by gel electrophoresis using 6% polyacrylamide gel in 0.5 × TBE buffer at a voltage of 80 V.
[0078] The sgc8 aptamer probe labeled with the FAM fluorescent group used is as follows:
[0079] 5'-FAM-TATGTCTCGAGATGGTCCATTTTTTATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGTTAGA-3'.
[0080] Figure 4 A is a gel electrophoresis analysis of the DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC) incubated in 10% fresh mouse serum at different time points. The experimental results show that sgc8-eNC has good serum stability, and even when incubated for 24 hours, the material is basically not degraded.
[0081] Example 3 Targeting stability analysis of DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC)
[0082] First, a DNA tetrahedron-based targeted DNA nanocluster material was constructed according to the method of Example 2 (the difference is that the original sgc8 aptamer probe was replaced by a sgc8 aptamer probe labeled with a FAM fluorescent group), and then the samples were mixed with fresh mouse serum, so that the final serum content was 10 vol%, and then incubated at 37 ° C for 4 and 8 hours to obtain the pretreated targeted DNA nanocluster material. Then, 30 μL of the pretreated targeted DNA nanocluster material and 170 μL of DMEM culture medium were added to a 24-well cell culture plate in which HeLa cells were pre-cultured, and cultured for 2 h in a humidified atmosphere of 37 ° C and 5% CO2. After incubation, the HeLa cells were digested with EDTA-free trypsin and continuously resuspended in 1 mL 1×PBS buffer (pH = 7.4). The fluorescence intensity was analyzed by counting at least 10,000 cells on a flow cytometer.
[0083] Figure 4B is the targeting stability analysis data of the DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC) after incubation for different time periods in 10 vol% fresh mouse serum. The fluorescence intensity obtained by flow cytometry represents the targeting stability of sgc8-eNC. Figure 4 As can be seen in B, even after sgc8-eNC was incubated in 10 vol% fresh mouse serum for 8 h, its targeting stability remained unchanged, proving that sgc8-eNC has good targeting stability.
[0084] Example 4 Application of DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC) in cell targeting recognition
[0085] First, a DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC) was constructed according to the method of Example 1 (T5 probes labeled with FAM fluorescent group were used to replace the original T5 probe assembly material).
[0086] The FAM fluorescent group-labeled T5 probe used is:
[0087] 5'-p-GCGAGTATGGAGTCAACTGCC / FAMdT / TCCACGTGATAGGATCGAATGCTGGATACGT-3'.
[0088] For suspension cells (CEM and Ramos), remove 5 × 10 4cells and centrifuged (1200 RPM, 5 minutes) to obtain a cell pellet. After washing the cells twice with D-PBS buffer (final concentration of glucose 4.5 g / L, final concentration of magnesium chloride 5 mM) as washing buffer, the cell pellet was resuspended in 175 μL of binding buffer, which was prepared by adding bovine serum albumin (final concentration 1 mg / mL) and yeast extracted RNA (final concentration, 0.1 mg / mL) to the washing buffer. Then, 25 μL of sgc8-eNC was added and mixed well, and then incubated at 37°C for 2 hours in a humidified atmosphere of 5% CO2. The resulting solution was centrifuged (1200 RPM, 5 minutes), and the pellet was washed twice with washing buffer (500 μL), and then Hoechst 33342 was added at a concentration of 10 μg / mL and left at room temperature for 15 minutes. Subsequently, the cells were centrifuged (1200 RPM, 5 minutes) to remove the residual Hoechst 33342 and resuspended in 20 μL of binding buffer. The cell samples were placed in a confocal dish and confocal laser scanning was performed on a Leica SP8 laser scanning confocal microscope. The excitation wavelength of Hoechst 33342 was 405 nm, and the excitation wavelength of FAM was 488 nm.
[0089] For adherent cells (HeLa and L02), 5 × 10 4 Cells were cultured in 24-well plastic plates, covered with round coverslips and cultured in DMEM complete medium (containing 10 vol% FBS and 1 wt% penicillin-streptomycin) at 37°C in a humidified incubator with 5% CO2 overnight. After washing the cells three times with 1× PBS buffer (pH = 7.4), 25 μL sgc8-eNC and 175 μL DMEM complete medium were added, and then incubated for 2 hours at 37°C in a humidified atmosphere with 5% CO2. Next, the cells were washed twice with 1× PBS buffer (pH = 7.4) and fixed with 4% paraformaldehyde for 15 minutes. After washing again with 1× PBS buffer (pH = 7.4), the cells were stained with Hoechst 33342 (10 μg / mL) at room temperature for 5 minutes. Finally, the cells were washed twice with 1× PBS buffer (pH = 7.4) to remove residual Hoechst 33342. Finally, confocal laser scanning was performed on a Leica SP8 laser scanning confocal microscope. The excitation wavelength of Hoechst 33342 was 405 nm, and the excitation wavelength of FAM was 488 nm.
[0090] Figure 5Laser confocal imaging data of DNA tetrahedron-based targeted DNA nanocluster materials (sgc8-eNC) incubated with different cells. Figure 5 A and Figure 5 B is the cell imaging data of the sgc8 aptamer probe targeting cells (CEM and HeLa can highly express PTK7 protein, and the sgc8 aptamer probe can target and recognize this protein). It can be seen that sgc8-eNC is effectively taken up by CEM and HeLa cells, while the drug delivery system material without the addition of sgc8 aptamer as the control is basically not taken up. Figure 5 C is non-targeted cancer cell (Ramos), Figure 5 D is a normal human cell (L02), neither of which is recognized by the sgc8 aptamer, so neither the drug-loaded DNA nanocluster material without the addition of the aptamer nor the sgc8-eNC is taken up by these two cells. This phenomenon proves that sgc8-eNC has a precise targeting recognition effect and can specifically recognize target cells, which lays the foundation for the potential application of targeted drug delivery.
[0091] Example 5 Evaluation of drug loading capacity of the targeted drug delivery system (Dox-sgc8-NC) based on DNA tetrahedral nanoclusters
[0092] The method of Example 1 was used to construct a DNA tetrahedron-based targeted DNA nanocluster material (sgc8-eNC), and then the drug loading capacity of Dox-sgc8-NC was investigated and analyzed using doxorubicin hydrochloride, an anthracycline drug, as a model. The specific experimental steps are as follows:
[0093] In order to evaluate the drug loading capacity of Dox-sgc8-NC for the anticancer drug doxorubicin (Dox), Dox at a fixed concentration of 2 μM was mixed with sgc8-eNC at different concentrations in 1×T4 DNA ligase buffer and incubated overnight at 37 °C to form a stable targeted drug delivery system based on DNA tetrahedral nanoclusters. The fluorescence spectrum was tested using a Hitachi F-7000 fluorescence spectrometer with a xenon lamp as the excitation light source.
[0094] Figure 6A is the drug loading evaluation data of Dox-sgc8-NC. Thanks to the large number of hybrid base pairs, sgc8-eNC can be well loaded with chemical anticancer drugs such as doxorubicin (Dox) in space. Due to Förster resonance energy transfer, the fluorescence of Dox is quenched after preferential insertion between GC base pairs. Then, the amount of Dox loaded into sgc8-eNC was evaluated by monitoring the change in Dox fluorescence intensity. The experimental results show that with the increase of sgc8-eNC concentration, the fluorescence intensity of Dox solution gradually decreases. 350 pM sgc8-eNC can be loaded with 2 μM Dox mixed, and its drug loading capacity is as high as 1:5670 (that is, 1 molecule of sgc8-eNC can load 5670 molecules of Dox drug), which indicates that Dox-sgc8-NC has an ultra-high drug loading capacity.
[0095] Example 6 Stability evaluation of the targeted drug delivery system (Dox-sgc8-NC) based on DNA tetrahedral nanoclusters
[0096] A targeted drug delivery system (Dox-sgc8-NC) based on DNA tetrahedral nanoclusters was constructed using the method of Example 1, and the stability of Dox-sgc8-NC was then investigated and analyzed. The specific experimental steps are as follows:
[0097] The constructed Dox-sgc8-NC was subjected to stability evaluation experiments in a microdialysis device (3.5KMWCO) in 1×PBS buffer (pH = 7.4). First, 100 μL of Dox-sgc8-NC was added to the microdialysis device, and an equal amount of free Dox (20μM) was added to another device as a control sample. The microdialysis device was kept on 3 mL of 1×PBS buffer (pH = 7.4) and dialyzed at room temperature and in the dark. 200 μL of solution was taken out from the dialysate at different time points (0, 1, 2, 4, 8, 14, 24, 48h), and the fluorescence intensity of different dialysates was measured on a Hitachi F-7000 fluorescence spectrometer. Under a xenon lamp as the excitation light source, an excitation wavelength of 495 nm was selected, and the fluorescence spectrum in the range of 500 to 700 nm was collected. Finally, 200 μL of sample was returned to the dialysate to keep the original volume unchanged.
[0098] Figure 6 B is the stability analysis data of Dox-sgc8-NCs. Compared with the rapid diffusion of the free drug solution, the drug diffusion efficiency of Dox-sgc8-NCs is negligible, which indicates that the Dox payload in Dox-sgc8-NCs is stable and can prevent the leakage of the drug in the blood circulation.
[0099] Example 7 Application of DNA tetrahedral nanoclusters-based targeted drug delivery system (Dox-sgc8-NC) in bioimaging and tumor targeted drug delivery
[0100] A targeted drug delivery system (Dox-sgc8-NC) based on DNA tetrahedral nanoclusters was constructed using the method of Example 1. Next, the application of Dox-sgc8-NC in biological imaging and tumor targeted drug delivery was explored. The specific experimental steps are as follows:
[0101] First, HeLa cells (1.0×10 cells) were inoculated subcutaneously in the right axilla of BALB / c male nude mice (about 20 g, 4-6 weeks old). 7 The HeLa tumor-bearing mouse model was established.
[0102] Bioimaging application: First, a targeted drug delivery system (Dox-sgc8-NC) based on DNA tetrahedral nanoclusters was constructed according to the method of Example 1 (the difference is that the T5 probe labeled with Cy5 fluorescent group is used to replace the original T5 probe). When the tumor volume of tumor-bearing mice reaches about 400 mm 3 Dox-sgc8-NC was injected through the tail vein at 4 pm. After the mice were anesthetized, fluorescence imaging of the mice or organs was performed on the IVIS imaging spectral system (640 nm filter excitation) to detect the biodistribution of the DNA nanocluster precision targeted drug delivery system materials in the mice.
[0103] The Cy5-modified DNA tetrahedral assembly probe 5 (FAM-T5) probe used was: 5'-P-GCGAGTATGGAGTCAACTGCC / Cy5dT / TCCACGGTGATAGGATCGAATGCTGGATACGT-3'.
[0104] Application of tumor targeted drug delivery: First, a targeted drug delivery system (Dox-sgc8-NC) based on DNA tetrahedral nanoclusters was constructed using the method of Example 1. When the mouse tumor volume reached an appropriate size (about 100 mm 3 ), normal saline (control group), free Dox or Dox-sgc8-NC (Dox dose 2.0 mg / kg) were injected into the tail vein every 3 days for 18 consecutive days. The mice were kept on a normal diet during the whole experiment. Tumor volume was estimated with a vernier caliper every 3 days before the new administration, and the formula (a 2 b) / 2, where a and b are the width and length of the tumor, respectively.
[0105] Figure 7A is the application of Dox-sgc8-NC in biological imaging. It can be clearly observed that 4 hours after tail vein injection, Dox-sgc8-NC accumulated in the tumor site and the fluorescence value reached the highest. After 8 hours, a large amount of Dox-sgc8-NC delivered to the tumor site was gradually cleared, showing obvious permeability and retention effects. In order to more accurately observe the distribution of Dox-sgc8-NC in each tissue and tumor, mice were killed 4 hours after tail vein injection of nanomaterials, and the main organs (heart, liver, spleen, lung and kidney) and tumor tissues of mice were collected, and in vitro fluorescence intensity images were obtained ( Figure 7 A). The results showed that the fluorescence of Dox-sgc8-NC was significantly enhanced in tumor tissue, which provided further evidence for its tumor targeting.
[0106] Figure 7 B shows the tumor volume growth of tumor-bearing mice (HeLa) after targeted drug delivery of DNA nanocluster precision targeted drug delivery system. After observing that Dox-sgc8-NC can accurately target the tumor site, free doxorubicin (FreeDox) and Dox-sgc8-eNC were injected into HeLa tumor-bearing nude mice through the tail vein. Another group of mice were injected with saline as a control under the same conditions. Before treatment, all mice showed similar tumor growth trends. Figure 7 B shows the changes in tumor volume. Tumors treated with saline alone grew fastest, reaching ∼3000 mm after 18 days of treatment. 3 , while in mice treated with free Dox, a slight reduction in tumor size was found, which may be due to insufficient drug accumulation at the tumor site. Compared with the control group, the tumor growth of mice in the Dox-sgc8-eNC experimental group was greatly inhibited (about 8.7 times that of the saline group), indicating that Dox-sgc8-eNC can be used for targeted drug delivery therapy of tumors.
[0107] Example 8 Construction of a universal DNA nanocluster targeted drug delivery system and its feasibility analysis
[0108] A targeted drug delivery system based on DNA tetrahedron nanoclusters was constructed by referring to the method of Example 1, and laser confocal imaging analysis was performed on the newly constructed DNA nanocluster precision targeted drug delivery system. The specific experimental steps are as follows:
[0109] The method of Example 1 was used to construct DNA tetrahedron-based targeted DNA nanocluster materials AS1411-eNC and S6-eNC, respectively, except that the sgc8 aptamer was replaced with AS1411 aptamer or S6 aptamer, and then the targeting properties were tested. The aptamers used are as follows:
[0110] AS1411 nucleic acid aptamer: 5'-TATGTCTCGAGATGGTCCATTTTTTGGTGGTGGTGGTTGTGGTG
[0111] GTGGTGG-3';
[0112] S6 nucleic acid aptamer: 5'-TATGTCTCGAGATGGTCCATTTTTTTGTGGCCAGTCACTCAATTGG
[0113] GTGTAGGGGTGGGGATTGTGGGTTG-3'.
[0114] Figure 8 A shows the construction of AS1411-eNC targeting MCF-7 cancer cells, which was evaluated using laser confocal imaging; Figure 8 B shows the construction of S6-eNC targeting A549 cancer cells, which was evaluated using laser confocal imaging; all of the above proves that the precise targeted drug delivery system based on DNA tetrahedral nanoclusters has good versatility and application potential.
[0115] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.
Claims
1. A targeted drug delivery system based on DNA tetrahedral nanoclusters, characterized in that: The targeted drug delivery system comprises DNA tetrahedron, T4 DNA ligase, sgc8 nucleic acid aptamer probe and anticancer drug; The DNA tetrahedron is assembled from the following 7 DNA probes: T1: 5'-p-AGGAGATACACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCGATCAGGCAGGGTCCAAT-3', T2: 5'-p-GCAGTTGACACGAACATTCCTAAGTCTGAAATTTATCCATCGCCATAGTAGACCTATCACCGTGGAAG-3', T3: 5'-ATGGACCATCTCGAGACATATTTCGTGTAGCAAGCTGTAATCGACTCTACCCTAAGTAAGCAAGACACAACTACTATGGCGATGGATAAA-3', T4: 5'-p-TAAGCCAGCCATAAGTCAGTATCTCCTATTGGACCCTGCCTGAACACTGATCCG-3', T5: 5'-p-GCGAGTATGGAGTCAACTGCCTTCCACGGTGATAGGATCGAATGCTGGATACGT-3', T6: 5'-p-CAGCATTCGAAGTCCAGTTTCTGGACATGTGTCTTGCTTACTTAGGGTAGAGAACCACGTTTCGTGGTAGACTTATGGC-3', LS: 5'-p-TGGCTTACGGATCAGTGAACCATACTCGCACGTATC-3'; The sgc8 nucleic acid aptamer probe is: 5'-TATGTCTCGAGATGGTCCATTTTTTATCTAACTGCTGCGCCGCCGGGAAAATACTGTACGGTTAGA-3'; The anticancer drug is an anthracycline anticancer drug; The method for constructing the targeted drug delivery system based on DNA tetrahedral nanoclusters comprises the following steps: S1: Construction of targeted DNA nanocluster materials based on DNA tetrahedron: S1-1: Take 0.5 µL of each of the DNA probes T1~T6 and LS, each with a concentration of 10 µM, add them together with 2.5 µL of 10×T4 DNA ligase buffer and 18 µL of ultrapure water into a 0.5 mL centrifuge tube and mix evenly using a micropipette; S1-2: placing the mixed solution obtained in step S1-1 on a metal heating block, heating the mixture at 90°C for 5 minutes, and then gradually cooling the mixture to room temperature to ensure successful assembly of the DNA tetrahedron; S1-3: After step S1-2 is completed, 0.5 µL of 10 µM sgc8 aptamer probe is added to the reaction solution and incubated at 37 °C for 2 h to obtain the sgc8-configured DNA tetrahedral structure; S1-4: After step S1-3, add 0.5 µL of 400 U / µL T4 DNA ligase to the reaction solution and incubate overnight at 16°C to promote the assembly of targeted DNA nanoclusters; S1-5: After step S1-4 is completed, the reaction solution is inactivated at 65° C. for 10 minutes to obtain the DNA tetrahedron-based targeted DNA nanocluster material sgc8-eNC; S2: Construction of targeted drug delivery system based on DNA tetrahedral nanoclusters: The sgc8-eNC and the anticancer drug were co-incubated in 1×T4 DNA ligase buffer, wherein the final concentration of sgc8-eNC was 0 - 3.5 nM, the final concentration of the anticancer drug was 0 - 20 µM, and the incubation conditions were: overnight incubation at 37°C in a dark environment. After the incubation was completed, the targeted drug delivery system based on DNA tetrahedral nanoclusters was obtained.
2. A universal targeted drug delivery system modified from the targeted drug delivery system according to claim 1, characterized in that: The universal targeted drug delivery system is obtained by changing the sequence of the nucleic acid aptamer probe in the drug delivery system according to the target cells.
3. The universal targeted drug delivery system according to claim 2, characterized in that: The universal targeted drug delivery system is obtained by changing the sequence of the nucleic acid aptamer probe in the drug delivery system for the target cell MCF-7 human breast cancer cell; the sequence of the changed nucleic acid aptamer probe is: 5'-TATGTCTCGAGATGGTCCATTTTTTGGTGGTGGTGGTTGTGGTGGTGGTGG-3'.
4. The universal targeted drug delivery system according to claim 2, characterized in that: The universal targeted drug delivery system is obtained by changing the sequence of the nucleic acid aptamer probe in the drug delivery system for the target cell A549 adenocarcinoma human alveolar basal epithelial cells; the sequence of the changed nucleic acid aptamer probe is: 5'-TATGTCTCGAGATGGTCCATTTTTTTGTGGCCAGTCACTCAATTGGGTGTAGGGGTGGGGATTGTGGGTTG-3'.
5. The use of the targeted drug delivery system based on DNA tetrahedral nanoclusters as claimed in claim 1 in the preparation of targeted tumor drugs, characterized in that: The tumor is selected from leukemia and cervical cancer.
6. Application of the targeted drug delivery system based on DNA tetrahedral nanoclusters as claimed in claim 1 in biological imaging.
Citation Information
Patent Citations
Nucleic acid nano device with cancer cell and mitochondria dual targeting
CN114053425A
